SpliceBio, a Barcelona, Spain-based biotechnology company exploiting Protein Splicing to develop gene therapies, raised €50M in Series A funding.
The financing was co-led by UCB Ventures and existing shareholder Ysios Capital and joined by new investors New Enterprise Associates (NEA), Gilde Healthcare, Novartis Venture Fund, and existing shareholder Asabys Partners.
The company, which was seeded in 2020 by Ysios Capital and Asabys Partners, intends to use the funds to build a pipeline of Protein Splicing gene therapy programs, while advancing the lead program in Stargardt disease to the clinic.
Led by CEO Miquel Vila-Perelló, SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. The company’s proprietary platform enables efficient delivery of large genes with adeno-associated vectors (AAV), overcoming the most fundamental challenge in the quest to curing a broad range of genetic diseases. SpliceBio’s platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research.
Following the closing of the financing, the Board of SpliceBio chaired by Jean Philippe Combal will include: Erica Whittaker, UCB Ventures; Joël Jean-Mairet, Ysios Capital; Ed Mathers, NEA; Arthur Franken, Gilde Healthcare; Beat Steffen, Novartis Venture Fund; and Miquel Vila-Perelló, CEO.
FinSMEs
21/02/2022